Puregon

Description overdue on 13.10.2011

Related Articles:

• Analogs sonapaks
• Tablets Dermazol
• Valtrex
• Eye drops of potassium iodide

Tweet

The main active substance - follitropin beta . Puregon belongs to the group Follicle-stimulating drugs . The preparation for the shortage FSH , Has a strong estrogen-like activity, stimulates the synthesis of Steroids   and production follicles . Puregon during the procedure artificial insemination   induces a greater number of follicles.

Indications:

Female infertility Caused by the hypothalamic-pituitary disorders stimuliyatsiya superovulation on the eve of technology IVF . polycystic ovary syndrome   ( anovulation ) hypogonadotropic gonadizm .

Contraindications:

Ovarian tumors, uterine hypothalamus . pituitary , Mammary gland, primary ovarian insufficiency, uterine bleeding (the cause of which is unknown) hypertrophy , Ovarian cysts, various kinds and types of malformations of sexual organs and systems that are incompatible with childbearing, uterine fibroma , Pregnancy, expressed violations of the liver, kidneys, lactation.

Side effect:

Pain in the abdomen, dyspepsia, nausea - a syndrome caused by increased stimulation of the ovaries. Ovarian cysts, a significant increase in their size, susceptibility to fractures, pleurorrhea . ascites , Weight gain, ectopic pregnancy . thromboembolism   (arterial), local reactions (swelling, hematoma, pain), multiple pregnancy, allergy .

Overdose:

Data on drug overdose Puregon not. It is theoretically possible development of the syndrome of increased ovarian stimulation. In overdose, symptoms of increased stimulation of introduction of unwanted drug is stopped. It is necessary to take measures to prevent conception, not to introduce CG. Treatment is focused on relief of symptoms and signs of increased ovarian stimulation.

Mode of application:

Puregon administered intramuscularly or subcutaneously. According to the results US , The level of concentration Estradiol   determine the individual dose. Anovualyatornoe infertility : An initial dose of 50 IU, the course lasts a week. If the ovaries do not respond, then the dose is increased (until follicle growth or increase the level of estradiol). At the end of treatment ovulation is induced by human CG. At higher concentrations of estradiol and follicle growth gradually reduce the dose, hCG is not administered, are protected from conception to prevent multiple gestations. Superovulation   artificial fertilization: for the first 4 days administered 150 IU, subsequent dose picked individually, depending on the response and the response of the ovaries. The maintenance dose is on average up to 375 IU (in tech. 6-12dn.). If three follicle reached a diameter of 15-20 mm, estradiol reached 400 pg / ml for 1 follicle then proceed to the final phase of follicle maturation induction (hCG is administered). Aspiration eggs   It carried out after 34 hours.

Special instructions:

Before and during treatment require regular ultrasound to monitor the level of follicular development, to determine the level Estradiol . Before treatment is necessary to eliminate all possible endocrine diseases (pituitary, adrenal, thyroid). It should be borne in mind that after the induction of multiple pregnancies may develop. In women with abnormal uterine tubes substantially increases the risk of ectopic pregnancy (caused by abnormalities of the fallopian tubes). The risk of miscarriage by artificial insemination is significantly higher than with natural conception. With symptoms of ovarian hyperstimulation it is necessary to stop treatment, to take measures to prevent the occurrence of conception, hCG is not administered. In the course of treatment were observed the formation of antibodies to the producer, and follitropin beta.

Drug Interactions:

Puregon pharmaceutically fully compatible with other drugs. After the suppression of the ovaries GnRH agonists   It may require a higher dose to achieve the full operation of the ovaries.